MedPath
HSA Approval

ABIRATERONE-TEVA FC TABLET 250 MG

SIN16416P

ABIRATERONE-TEVA FC TABLET 250 MG

ABIRATERONE-TEVA FC TABLET 250 MG

January 8, 2022

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Licence HolderTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

ORAL

Medical Information

L02BX03

abiraterone

Manufacturer Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA Pharmaceutical Industries Ltd.

Active Ingredients

Abiraterone Acetate

250 mg

Abiraterone

Documents

Package Inserts

Abiraterone-TEVA FC Tablet 250mg PI.pdf

Approved: January 8, 2022

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ABIRATERONE-TEVA FC TABLET 250 MG - HSA Approval | MedPath